Actionable news
0
All posts from Actionable news
Actionable news in INSY: Insys Therapeutics, Inc.,

Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss

Headquartered in Menlo Park, CA, Pacific Biosciences of California Inc. PACB, a pioneer in the field of single molecule long resequencing technology (SMRT), reported a loss of 26 cents per share in the second quarter of 2017. The figure is 2 cents wider than the Zacks Consensus Estimate. In fact, the figure is also wider than the loss of 21 cents reported in the year-ago quarter.

Revenues of $20.07 million missed the Zacks Consensus Estimate of $23 million and declined 3.2% on a year-over-year basis.

Q2 Highlights

Product and Services revenues rose 17% to $20.07 million on a year-over-year basis.

Gross margin in the second quarter was 39.9% of net revenue versus 41.1% in the year-ago quarter. Research & development (R&D) expenses totaled $16.9 million, lower than $17.5 million reported in the year-ago quarter.

Pacific Biosciences of California, Inc. Price, Consensus and EPS Surprise

Pacific Biosciences of California, Inc. Price, Consensus and EPS Surprise | Pacific...


More